GLTO Company Profile and Key Details

GLTO has shown sold momentum, gaining 27.98% over the past week and 191.49% over the past quarter, though year-to-date performance is up 21.36%. Short-term trend indicators are bearishly aligned (SMA20 8.9%, SMA50 13.08%, SMA200 146.48%). The stock’s 14-day RSI is 55.75 (neutral), while the ATR of 2.95 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.3% below its high and over 1381.59% above its low.

Galecto, Inc. has 1.32 million shares outstanding. The public float is 1.22 million shares, elevated short interest at 2.15% of float. This equals 27.46 thousand shares. The short ratio is 1.0 days. Institutional investors hold 12.72% of the float. Insiders own 3.68%. Novo Holdings A/S holds 2.50 million shares, Khuong Chau Quang has 1.03 million shares and Christgau Stephan has 546.14 thousand shares. Over the past six months, insider transactions show net selling. They sold 1.09 thousand shares across 3 transactions.

Galecto, Inc. generated EPS of -$12.10 over the past year. Five-year average earnings growth is 14.83%. Wall Street analysts project EPS growth of 56.9% annually over the next five years. The latest quarter delivered EPS of -$0.62. The next quarter is forecast at -$0.11. Next year's EPS is expected at $19.48. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $46.00 to $32.00. The high target offers 113.16% upside. The low target suggests 48.29% downside. The mean target is $39.80. This offers 84.43% upside. Galecto, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 59.89%. The prior quarter beat by 2216.35%. Over the last six quarters, Apple has recorded several small beats. These include -51.22% in April 29, 2024.

Damora Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $12.19. This means the shares are trading above this model’s fair value.

Damora Therapeutics, Inc. (NASDAQ:GLTO) closed at $21.58 USD, losing -$0.75 (-3.36%) from the previous close of $22.33. The stock is currently mid-range between its 52-week high and low $2.01 and $38.33. With a market capitalization of about $34.47 million, Damora Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.60). Key stats such as the average daily volume over the past year has been around 480.39 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Damora Therapeutics, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Jennifer A. Jarrett, the company employs approximately 7 people and listed since October 28, 2020. Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.

Our AI price prediction model suggests that Galecto, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.45%, with price expected at $22.30 by June 19, 2026, within a range of $21.49 to $23.13 3-Month Outlook: Projected fall of -8.83%, reaching $20.24 by September 03, 2026, with a range of $19.26 to $21.00. 1-Year Outlook: Projected loss of -45.81%, with price at $12.03 by June 04, 2027, within a range of $6.36 to $17.53.

Galecto, Inc. (NASDAQ:GLTO) shares are up 21.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Galecto, Inc. trading at a premium to the broader market with a P/E of -1.08. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.12, suggesting -9.37% downside. Our AI forecast model points to short-term strength (0.45% over two weeks), a medium-term fall (-8.83% over three months), and a longer-term loss (-45.81% over one year), with expected trading ranges indicating moderate volatility.

Galecto, Inc. trades at a P/E ratio of -1.08, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.07 suggesting the stock is closer to book value. The P/FCF stands at -1.39, also below market averages.